Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Can someone enlight me with transaminase mistery...

<< Previous

Bullboard Posts

Next >>

Comment by Edou111on Aug 24, 2021 8:33am

311 Views

Post# 33753748

RE:RE:Can someone enlight me with transaminase mistery...

Thanks Walkoverthestrt for your reply. Are you telling me that naproxen as a stand alone would have produced the same LTE results ? So on top of the GI safety and the Womac score, Antibe needs to provide better LTE results than Naproxen ? Or HS2 do potentiate not only the therapeutics of Naproxen but also its side effects ?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale